Key Takeaways Rezolute stock rose 12.1% after an FDA meeting on the ersodetug program for congenital HI.RZLT discussed phase III data, noting placebo effects and SMBG limits impacted primary endpoint results.Rezolute plans to submit full data to the FDA, with an update expected in the second half of 2026.Shares of Rezolute (RZLT) gained 12.1% on Tuesday after the company announced productive outcomes from an in-person Type B meeting with the FDA that was held last week to discuss the phase III safety and ef ...